Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Allergan PLC, consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net revenues 3,604,400 4,351,000 4,050,700 4,090,100 3,597,100 4,079,700 3,911,400 4,124,200 3,672,100 4,326,100 4,034,300 4,007,400 3,572,900 3,864,300 3,622,200 3,684,800 3,399,300 2,664,500 4,088,900 5,755,000 2,562,600
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights (623,100) (704,000) (639,000) (652,300) (497,800) (590,000) (596,800) (481,800) (522,800) (580,900) (586,500) (550,200) (450,400) (479,700) (462,200) (441,500) (477,400) (417,300) (1,242,900) (2,130,100) (1,020,100)
Gross profit 2,981,300 3,647,000 3,411,700 3,437,800 3,099,300 3,489,700 3,314,600 3,642,400 3,149,300 3,745,200 3,447,800 3,457,200 3,122,500 3,384,600 3,160,000 3,243,300 2,921,900 2,247,200 2,846,000 3,624,900 1,542,500
Research and development (430,000) (452,500) (474,500) (450,000) (435,000) (678,100) (424,200) (689,200) (474,700) (408,200) (442,600) (489,400) (759,900) (913,300) (622,800) (636,500) (403,100) (325,400) (1,260,500) (454,900) (317,700)
Selling and marketing (972,100) (883,000) (901,400) (873,300) (804,000) (841,600) (755,600) (853,400) (800,000) (877,700) (832,800) (935,200) (869,100) (836,800) (796,000) (866,800) (766,800) (641,600) (721,800) (981,000) (569,600)
General and administrative (401,300) (756,600) (1,092,700) (324,200) (308,300) (352,000) (289,200) (334,100) (295,900) (389,100) (336,900) (459,800) (316,100) (440,000) (361,200) (343,200) (329,500) (393,500) (351,400) (480,200) (540,500)
Amortization (1,416,400) (1,517,500) (1,537,700) (1,402,000) (1,399,400) (1,569,100) (1,588,500) (1,697,100) (1,697,600) (1,922,200) (1,781,000) (1,757,900) (1,736,000) (1,638,500) (1,609,100) (1,633,100) (1,589,700) (1,431,900) (1,560,200) (1,673,500) (787,800)
Goodwill impairments (913,000) — — (1,085,800) (2,467,000) (2,841,100) — — — — — — — — — — — — — — —
In-process research and development impairments — — — (436,000) — (6,600) — (276,000) (522,000) (207,000) (202,000) (703,300) (340,000) (427,000) (42,000) (268,900) (6,000) (14,000) (300,000) (197,600) —
Asset sales and impairments, net (148,100) (314,000) (2,000) (129,400) 5,200 (2,585,300) 400 (259,600) (13,100) (31,500) (3,874,800) (14,000) (7,400) (29,000) 4,700 17,600 1,700 (271,200) 4,400 (600) (4,600)
Operating income (loss) (1,299,600) (276,600) (596,600) (1,262,900) (2,309,200) (5,384,100) 257,500 (467,000) (654,000) (90,500) (4,022,300) (902,400) (906,000) (900,000) (266,400) (487,600) (171,500) (830,400) (1,343,500) (162,900) (677,700)
Interest income 21,200 25,300 20,500 9,700 21,300 11,600 10,000 6,300 17,300 14,700 11,100 16,600 25,300 46,400 18,100 2,500 2,900 3,200 3,800 2,600 1,800
Interest expense (184,500) (191,900) (193,900) (195,400) (201,800) (210,200) (220,400) (230,000) (250,600) (263,300) (265,200) (277,400) (289,700) (292,700) (324,300) (345,800) (332,800) (341,300) (340,200) (339,900) (171,900)
Other income (expense), net (24,900) 21,200 2,500 (4,700) 13,800 (9,900) 130,000 215,400 (78,800) (70,700) (1,310,300) (133,500) (1,922,800) 35,000 33,600 150,100 500 12,600 200 (48,700) (197,900)
Other income (expense), net (188,200) (145,400) (170,900) (190,400) (166,700) (208,500) (80,400) (8,300) (312,100) (319,300) (1,564,400) (394,300) (2,187,200) (211,300) (272,600) (193,200) (329,400) (325,500) (336,200) (386,000) (368,000)
Income (loss) before income taxes and noncontrolling interest (1,487,800) (422,000) (767,500) (1,453,300) (2,475,900) (5,592,600) 177,100 (475,300) (966,100) (409,800) (5,586,700) (1,296,700) (3,093,200) (1,111,300) (539,000) (680,800) (500,900) (1,155,900) (1,679,700) (548,900) (1,045,700)
(Provision) benefit for income taxes 1,866,800 104,700 (18,100) (301,600) 68,600 1,296,700 (213,400) 5,200 682,200 3,918,300 1,638,800 581,200 532,100 1,071,200 158,900 258,200 408,700 170,700 824,900 307,300 259,000
Net income (loss) from continuing operations, net of tax 379,000 (317,300) (785,600) (1,754,900) (2,407,300) (4,295,900) (36,300) (470,100) (283,900) 3,508,500 (3,947,900) (715,500) (2,561,100) (40,100) (380,100) (422,600) (92,200) (985,200) (854,800) (241,600) (786,700)
Income (loss) from discontinued operations, net of tax — — — — — — — — — (385,300) (6,100) (8,400) (3,100) 41,300 15,601,900 (77,300) 348,600 355,900 6,157,400 — 274,400
Net income (loss) 379,000 (317,300) (785,600) (1,754,900) (2,407,300) (4,295,900) (36,300) (470,100) (283,900) 3,123,200 (3,954,000) (723,900) (2,564,200) 1,200 15,221,800 (499,900) 256,400 (629,300) 5,302,600 (241,600) (512,300)
(Income) loss attributable to noncontrolling interest (1,000) 100 (1,200) (4,100) (700) (4,000) (1,600) (2,400) (2,200) (1,900) (1,700) (2,000) (1,000) (1,800) (1,800) (1,800) (700) (1,600) (1,400) (1,500) 300
Net income (loss) attributable to shareholders 378,000 (317,200) (786,800) (1,759,000) (2,408,000) (4,299,900) (37,900) (472,500) (286,100) 3,121,300 (3,955,700) (725,900) (2,565,200) (600) 15,220,000 (501,700) 255,700 (630,900) 5,301,200 (243,100) (512,000)
Dividends on preferred shares — — — — — — — — (46,400) (69,600) (69,600) (69,600) (69,600) (69,600) (69,600) (69,600) (69,600) (69,600) (69,600) (69,600) (23,200)
Net income (loss) attributable to ordinary shareholders 378,000 (317,200) (786,800) (1,759,000) (2,408,000) (4,299,900) (37,900) (472,500) (332,500) 3,051,700 (4,025,300) (795,500) (2,634,800) (70,200) 15,150,400 (571,300) 186,100 (700,500) 5,231,600 (312,700) (535,200)

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Income statement item Description The company
Net revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Allergan PLC net revenues increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Allergan PLC operating income (loss) increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Income (loss) before income taxes and noncontrolling interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan PLC income (loss) before income taxes and noncontrolling interest increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Net income (loss) attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan PLC net income (loss) attributable to shareholders increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.